Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami, M Takeda… - Oncogene, 2016 - nature.com
Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and
correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a …
被引用次数：104 相关文章

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and
correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a …

[引用][C] Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami, M Takeda… - Oncogene, 2015 - cir.nii.ac.jp
Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to
the epidermal growth factor receptor inhibitor erlotinib | CiNii Research CiNii 国立情報学研究所 …
[PDF] kindai.ac.jp

[PDF][PDF] Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami, M Takeda… - Oncogene, 2016 - med.kindai.ac.jp
Members of the human epidermal growth factor receptor (HER) family of proteins—which
includes HER1 (also known as epidermal growth factor receptor (EGFR)), HER2, HER3 and …

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami… - …, 2016 - kyushu-u.elsevierpure.com
Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and
correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a …

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami, M Takeda… - Oncogene, 2016 - go.gale.com
Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and
correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a …

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.

K Yonesaka, K Hirotani, H Kawakami, M Takeda… - Oncogene, 2015 - europepmc.org
Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and
correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a …
[PDF] researchmap.jp

[PDF][PDF] Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami, M Takeda… - Oncogene, 2015 - researchmap.jp
Members of the human epidermal growth factor receptor (HER) family of proteins—which
includes HER1 (also known as epidermal growth factor receptor (EGFR)), HER2, HER3 and …
[PDF] kindai.ac.jp

[PDF][PDF] Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami, M Takeda… - Oncogene, 2015 - med.kindai.ac.jp
Members of the human epidermal growth factor receptor (HER) family of proteins—which
includes HER1 (also known as epidermal growth factor receptor (EGFR)), HER2, HER3 and …

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

K Yonesaka, K Hirotani, H Kawakami, M Takeda… - Oncogene, 2016 - go.gale.com
Human epidermal growth factor receptor (HER) 3 is aberrantly overexpressed and
correlates with poor prognosis in non-small cell lung cancer (NSCLC). Patritumab is a …